Patents Represented by Attorney Sheldon O. Heber
-
Patent number: 8232274Abstract: Disclosed is a set of compounds useful as glucan synthase inhibitors having the generic structure of Formula I: wherein the various moieties A, D, R6, etc., are as defined in the specification. These compounds are useful in treating or preventing fungal infections in a patient.Type: GrantFiled: March 12, 2008Date of Patent: July 31, 2012Assignees: Albany Molecular Research, Inc., Merck Sharp & Dohme Corp.Inventors: Pauline C. Ting, Robert G. Aslanian, Jianhua Cao, David Won-Shik Kim, Rongze Kuang, Gang Zhou, Robert Jason Herr, Andrew John Zych, Jinhai Yang, Heping Wu, Nicolas Zorn
-
Patent number: 8178520Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R1, Ra, Rb, R3, R4, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.Type: GrantFiled: May 11, 2007Date of Patent: May 15, 2012Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpAInventors: Maria Emilia Di Francesco, Emanuela Nizi, Paola Pace, Vincenzo Summa
-
Patent number: 8158807Abstract: The present invention provides for a process for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate, an intermediate useful in the efficient preparation of (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof, processes for preparing (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof from the sulfonate intermediate and processes for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate.Type: GrantFiled: December 18, 2007Date of Patent: April 17, 2012Assignee: Schering CorporationInventors: Thierry Berranger, Patrice Demonchaux
-
Patent number: 7989438Abstract: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.Type: GrantFiled: July 15, 2008Date of Patent: August 2, 2011Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpAInventors: Immacolata Conte, Joerg Habermann, Angela Mackay, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
-
Patent number: 7879797Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.Type: GrantFiled: April 28, 2006Date of Patent: February 1, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David Olsen, Michael T. Rudd, Joseph P. Vacca
-
Patent number: 7795250Abstract: The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.Type: GrantFiled: June 8, 2005Date of Patent: September 14, 2010Assignee: Istituto di Ricerche di Biologia Molecolare P Angeletti SpAInventors: Stefania Colarusso, Immacolata Conte, Joerg Habermann, Frank Narjes, Simona Ponzi
-
Patent number: 7611868Abstract: Recombinant adenoviruses comprising modified fiber proteins which expand the tropism of the adenovirus in comparison to wild-type virus are disclosed. The modified fiber proteins described herein contain a peptide ligand for a cell surface binding site other than CAR comprising a 14 amino acid core sequence containing both fixed and variable amino acid residues. The invention includes isolated nucleic acid molecules encoding the modified adenovirus fiber proteins disclosed, as well as recombinant vectors and host cells containing said nucleic acid molecules. Methods of identifying peptide ligands that bind to cell binding sites other than CAR are included comprising screening a phage-display library of peptide ligands expressed within an adenovirus fiber knob context on CAR-negative cells.Type: GrantFiled: May 10, 2004Date of Patent: November 3, 2009Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Paolo Monaci, Laura Fontana
-
Patent number: 7598362Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.Type: GrantFiled: October 10, 2002Date of Patent: October 6, 2009Assignees: Merck & Co., Inc., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
-
Patent number: 7208282Abstract: The present invention identifies the presence of MCH-2R in the dog, ferret and rhesus monkey. MCH-2R is a G-protein coupled receptor that responds to MCH and is distinct from MCH-1R. MCH-2R polypeptide and nucleic acid sequences related to the dog, ferret, and rhesus monkey MCH-2R are described herein along with uses of such polypeptides and nucleic acids.Type: GrantFiled: May 28, 2002Date of Patent: April 24, 2007Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.Inventors: Carina Tan, Hideki Sano
-
Patent number: 7198910Abstract: The present application features two different forms of the human MCH receptor: (1) MCH-R2 and (2) MCH-R3. Such MCH receptors provide a target for achieving a beneficial affect in a patient and facilitate the screening of compounds that modulate MCH receptor activity or expression. Beneficial effects that can be obtained include increasing appetite, decreasing appetite, and reducing stress.Type: GrantFiled: July 10, 2000Date of Patent: April 3, 2007Assignee: Merck & Co., Inc.Inventor: Andrew D. Howard
-
Patent number: 7078215Abstract: Truncated HCV NS2/3 can be produced recombinantly and renatured into functional enzyme, useful in assays for modulators of activity and HCV function.Type: GrantFiled: March 14, 2001Date of Patent: July 18, 2006Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti, S.P.A.Inventors: Christian Steinkuhler, Michele Pallaoro, Armin Lahm
-
Patent number: 7034108Abstract: Peptides which are mimotopes of the hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) are provided, useful in obtaining antibodies and raising an immune response cross-reactive against different strains of HCV.Type: GrantFiled: May 14, 1999Date of Patent: April 25, 2006Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Alfredo Nicosia, Armin Lahm, Anna Tramontano, Riccardo Cortese
-
Patent number: 7029878Abstract: The present invention features melanin concentrating hormone receptor (MCH-R) chimeric and fusion proteins. MCH-R chimeric proteins comprise an MCH-R polypeptide region made up of at least two or more polypeptide regions characteristic of MCH-R found in different species. MCH-R fusion proteins comprise an MCH-R polypeptide region and a fluorescent protein region.Type: GrantFiled: March 14, 2001Date of Patent: April 18, 2006Assignee: Merck & Co., Inc.Inventor: Donald J. Marsh
-
Patent number: 7015008Abstract: The present invention features antibodies referred to herein as “MAb50-4” and “MAb184-10”, and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.Type: GrantFiled: September 25, 2001Date of Patent: March 21, 2006Assignee: Merck & Co., Inc.Inventors: Magang Shou, Qin Mei
-
Patent number: 6967237Abstract: The present invention features truncated ghrelin analogs active at the GHS receptor. Ghrelin is a naturally occurring modified peptide. The analogs can bind to the GHS receptor and, preferably, bring about signal transduction. Ghrelin analogs have a variety of different uses including being used as a research tool and being used therapeutically.Type: GrantFiled: May 25, 2001Date of Patent: November 22, 2005Assignee: Merck & Co., Inc.Inventor: Maria A. Bednarek
-
Patent number: 6960558Abstract: The present invention relates to methods for screening for anti-obesity agents using the ciliary neutrophic factor receptor.Type: GrantFiled: January 31, 2003Date of Patent: November 1, 2005Assignee: Instituto di Recerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Gennaro Ciliberto, Isabelle Gloaguen, Annalise Di Marco, Anna Demartis, Ralph Laufer, Riccardo Cortese
-
Patent number: 6955891Abstract: The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.Type: GrantFiled: April 28, 2003Date of Patent: October 18, 2005Assignee: Merck & Co., Inc.Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe
-
Patent number: 6906320Abstract: The present invention features mass spectrometry data analysis techniques that can be employed to selectively identify analytes differing in abundance between different sample sets. The employed techniques determine the statistical significance of changes to signals associated with mass-to-charge ratios (“m/z-intensity pairs”) between individual samples and sample sets. Based on the statistical significance, changes likely to indicate analyte level differences are identified. Based on intensities of the signals, ratios of analyte abundances can be determined.Type: GrantFiled: March 31, 2004Date of Patent: June 14, 2005Assignee: Merck & Co., Inc.Inventors: Jeffrey R. Sachs, Matthew C. Wiener, Nathan A. Yates
-
Patent number: 6867284Abstract: Fluorinated oligopeptides, especially those having 4,4-difluoro-2-amino butyric acid at the C terminus, may be effective inhibitors of hepatitis C virus NS3 protease. Examples of hexapeptides of the invention, optimized for binding in the S1 specificity pocket of the enzyme, may display IC50s at the sub-micromolar level. Embodiments of tripeptides of the invention, having a keto-acid group at the C-terminus are, likewise, potent inhibitors of NS3 protease.Type: GrantFiled: June 9, 1999Date of Patent: March 15, 2005Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Victor Matassa, Frank Narjes, Konrad Forster Koehler, Jesus Ontoria, Marco Poma, Antonella Marchetti
-
Patent number: RE43298Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Type: GrantFiled: April 22, 2011Date of Patent: April 3, 2012Assignees: Schering Corporation, Dendreon CorporationInventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry M. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang